Hosted on MSN1mon
Amycretin Shows Promising 22% Weight Loss in Trials-It May Rival Ozempic
Drug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight loss results comparable to those of popular GLP-1 injectables like ...
pharmaphorum4d
Novo Nordisk’s oral amycretin tops Wegovy in obesity trial
The drug, called amycretin and codenamed NN9487, is a dual agonist that targets both GLP-1 and amylin and is being developed in both oral and subcutaneous injection formulations. The oral form has ...
pharmaphorum4d
Novo Nordisk leaps on new obesity drug data
The new results with a once-weekly subcutaneous injection of amycretin – which is also being developed in a daily oral formulation – show that the combined GLP-1 and amylin agonist achieved up ...
Kiplinger2mon
Novo Nordisk Stock Surges On Weight Loss Drug Data and Analysts Say It's Still a Buy
The topline results from the Phase 1b/2a clinical trial showed that patients treated with Amycretin achieved a body weight loss of 9.7% in 20 weeks on 1.25 milligrams, 16.2% in 28 weeks on 5 ...
Morgan Stanley says REDEFINE-2 misses opportunity to differentiate in diabetes
Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety ...